BioLine Rx (STU:YP2) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:YP2 BioLine Rx Ltd STU:YP2
33 GF Score
Price €2.50
! 5 Warning Signs
View Full Analysis

What is BioLine Rx FFO per Share?

FFO per Share only applies to REITs.

STU:YP2
33GF Score
BioLine Rx Ltd STU:YP2
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLine Rx Business Description

Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
33GF Score

Get the complete analysis for STU:YP2

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.50
Price